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ABSTRACT
T he countries of Central Asia are still at the earliest stages of an HIV/AIDS epidemic. However, there is cause for serious concern due to: the steep growth of new HIV cases in the region; the established related epidemics of injecting drug use, sexually transmitted infections (STIs) and tuberculosis (TB); youth representing more than 40 percent of the total regional population; and the low levels of knowledge about the epidemics. The underlying causes for the interlinked epidemics of drug abuse, HIV/AIDS, STIs and TB in Central Asia are many, including drug production in Afghanistan and its distribution throughout the Former Soviet Union (FSU); unemployment among youth; imprisonment for drug use; overcrowding in prisons; and striking levels of poverty.
HIV/AIDS and tuberculosis may have a potentially devastating effect on human capital, economic development, and health systems reform. In Russia, economic analysis has described the significant future impact on health and health systems if the concentrated epidemic in that country goes unchecked (Ruhl etal. 2002) . The opportunity for prevention in low prevalence environments provides an imperative for action, because when HIV prevalence among high-risk groups reaches 20 percent or more, prevention is no longer possible and expensive treatment for AIDS and related opportunistic infections will overwhelm under funded health care systems such as those in Central Asia. Low prevalence, or nascent epidemics of HIV create little incentive for focused attention. However, through careful consideration of the potential for these epidemics to grow, the World Bank can help client countries incorporate effective prevention strategies into health systems development projects or into specific public health projects to address these infections.
Therefore, to address this impending crisis, the World Bank has initiated the study of HIV/AIDS, STIs, and TB in Central Asia. The Central Asia HIV/AIDS and TB Country Profiles were developed to inform Bank management and other stakeholders about the main characteristics of the epidemics in the sub region; to describe differences among the countries; and to develop an understanding of the main issues related to the prevention of HIV/AIDS and the control of TB. The Country Profiles summarize information available from Governments and partner organizations such as the UN agencies, USAID, and the Soros Foundation/OSI. It covers the following aspects: epidemiology; strategic and regulatory frameworks; surveillance; preventive, diagnostic, and treatment activities; non-governmental (NGO) and partner activities; and funding resources available. The Country Profiles are based on review of existing statistics and reports and on discussions with key stakeholders -Governments, donors, and NGOs -during several missions to Central Asia. In the following pages, we summarize the main issues identified in the initial assessment and the main recommendations for further study and action.
Further studies focusing on HIV/AIDS are being prepared for publication, with the following objectives:
(i) Estimate the potential epidemiological and economic impact of the HIV/AIDS epidemic in Central Asia; (ii) Identify key stakeholders and their roles in controlling the epidemic; (iii) Identify gaps in strategies, policies and legislation aimed at controlling the epidemic; (iv) Assess the institutional capacity, including of public health services and NGOs, to control the epidemic; and (v) Prepare the Bank's communication strategy on HIV/AIDS in Central Asia.
The Bank has initiated a Central Asia TB Study. It has also initiated the preparation of HIV/AIDS Components of Health Projects in Tajikistan and Uzbekistan, and is considering the possibility of assisting regional Governments in preparing a Central Asia HIV/AIDS and TB Project. Such a project would include regional and country-specific components, and would be partly financed by IDA grants.
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The World Bank
Extent and Likely Impact of the HIV/AIDS Epidemic in Central Asia
The HIV/AIDS epidemic is still at a low level in the countries of Central Asia, but this situation presents a dual challenge: first, to call attention to the projected epidemic so that policy-makers at the national level understand what lies ahead, given international evidence on the growth of HIV infection; and second, to plan, in the context of extremely limited resources, a rational response to HIV/AIDS throughout the sub region. In Central Asia, as in the rest of ECA, the epidemic is rather significantly under-measured, but it is clear to all that HIV incidence is increasing, following epidemics of intravenous drug use (IDU) and sexually transmitted illnesses (STI) throughout these countries. According Euro-HIV, countries in Central Asia have shown dramatic increases in numbers and rates of infection between 1996 and 2001 ( Table 1) . Some of these increases are due to improved surveillance of HIV infection (this phenomenon is known as reporting artifact), but nevertheless, all data point to a rapidly increasing epidemic. Official prevalence estimates of HIV infection among the adult populations vary between 0.14 percent in Kazakhstan to less than 0.01 percent in Tajikistan, Turkmenistan, and Uzbekistan (Table 2 ).
All Governments agree that drug trafficking and intravenous drug use have increased since 1995, most dramatically since the 2001 war in Afghanistan. When frontiers in Tajikistan and Uzbekistan opened, the prices of drugs decreased. Although the majority (60-90 percent) of reported HIV cases is among intravenous drug users, the proportion of cases attributed to heterosexual transmission has also been growing recently. Globally, IDUs, commercial sex workers (CSWs), men who have sex with men (MSM), and young people in general are recognized as the groups most at risk of HIV/AIDS. The overlap between IDUs and CSWs in this sub region is considered an added risk for transmission of the epidemic from highly vulnerable groups to vulnerable groups such as young people. Furthermore, occasional CSW practiced by female students and underreported homosexual behavior may present additional risks for rapid spread of the epidemic to youth in general. School dropouts, who are especially at risk of IDU and CSW, may deserve more targeted attention than they receive at present. Mobile populations such as truck drivers,
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mariners, the homeless, refugees, migrant workers, and trafficked women are also among the highly vulnerable groups, including in neighboring countries such as China. Therefore, it is expected that the incidence of HIV will increase among them in Central Asia as well. Trafficking of drugs, and women and children for prostitution, is of particular concern. Prisoners and institutionalized children are other groups that deserve additional study and targeted programs.
Officially reported cumulative HIV cases are shown in Table 3 . However, Centers for Disease Control and Prevention (CDC) surveillance data in Central Asia indicate that the total number of people living with HIV/AIDS is estimated to be about 90,000. Based upon projections for the year 2005, this number will rise to 1.65 million without concerted efforts to target interventions.
1 This growth may create a catastrophic impact at the household level and a significant impact on health services expenditures at the national level.
The Public Health Approach in Central Asia: Early Efforts
The Governments of Kazakhstan, Kyrgyz Republic, Tajikistan and Uzbekistan have approved HIV/AIDS Strategies prepared with assistance from the Joint United Nations Program on HIV/AIDS (UNAIDS).
2 These countries have established high-level multi-sectoral committees to coordinate strategy implementation. The situation is more tenuous in Turkmenistan, but the UNAIDS Thematic Group (TG) is assisting the Government to prepare a Strategy. The Strategies include multi-sectoral approaches and evidence-based interventions to the epidemic (Ball 1998, 2 WORLD BANK WORKING PAPER Burrows 2001): establishment of sentinel surveillance, harm reduction (HR), 3 prevention and treatment of STIs, and education of young people in general. All countries have approved AIDSrelated laws, are implementing multi-year and multi-sectoral programs to prevent further spread of HIV/AIDS, and have functional UNAIDS TGs, with Government, partner organizations, and NGO representation. However, strategy implementation is still quite limited throughout the sub region due to lack of political leadership, inadequate public knowledge, and limited funding for prevention.
Issues surrounding the legal framework on the production, sale, and use of drugs to treat HIV and related diseases; CSWs; homosexuality; and prevention and treatment of STIs varies from country to country. It is more advanced in Kazakhstan and Kyrgyz Republic and more conservative in Uzbekistan and Turkmenistan. The Government of Kazakhstan is considering decriminalization of drug use. The Kyrgyz Republic Parliament is reviewing a new Drug Law that softens penalties for drug use and could eventually consider decriminalization. Decriminalization of drug use is highly controversial, but Organization for Economic Cooperation and Development (OECD) countries such as Netherlands, Switzerland, and Portugal have adopted this approach (Van Het Loo etal. 2001; Swiss Expert Commission 1996) . Decriminalization may facilitate HIV/AIDS prevention efforts through destigmatization of IDUs, and it would diminish overcrowding in prisons, thereby reducing detention costs and TB transmission. Potential savings could be used to buy supplies (condoms, syringes) necessary for prevention of HIV/AIDS and pharmaceuticals necessary to treat TB, HIV/AIDS, and STIs.
Governments, UN agencies, bilateral agencies, and national and international NGOs are involved in prevention activities such as harm reduction and school-based reproductive health education throughout Central Asia, but these occur only as pilot activities. Scaling up prevention activities to cover the groups at most risk is needed to impact the epidemic, but Governments do not have the political will or resources necessary to do so. UN agencies have funded initial work with highly vulnerable groups, and most HR programs are implemented by the Soros Foundation/OSI through NGOS in Central Asian countries.
Additional resources and capacity will be necessary to: provide groups at risk with voluntary anonymous testing, education, and counseling (VCT); promote/market safer sex; treat STIs; provide replacement therapy for IDU; reduce demand for drugs; build capacity of public health services and NGOs to tackle the epidemic; and increase the political will and public knowledge necessary to address the epidemic openly and effectively. Former drug users and CSWs can be trained to engage in peer education about harm reduction and safe sex. More information is needed to determine the optimum approach to Mother to Child Transmission (MTCT) in the sub region. Currently, there are few data on the extent of this mode of transmission, while costs for screening all pregnant women may be quite excessive and not cost-effective in the current low-level epidemic situation.
Public Advocacy and Education
Evidence about knowledge, attitudes, and practices among decision-makers, opinion-makers, and health professionals about HIV/AIDS is deficient in the sub region. Some stakeholders (Governments, donors, and NGOs) are well aware of the IDU epidemic and the resulting growth of the HIV epidemic. However, all stakeholders recognize the low level of knowledge among health professionals, the low level of awareness about HIV/AIDS among highly vulnerable groups, and the low level of knowledge about the disease, and high level of stigmatization of people living with HIV/AIDS (PLWHA) among the general population. While some Government counterparts (Kazakhstan, Kyrgyz Republic, Tajikistan) are aware of the need to take action on politically difficult measures, others (Uzbekistan, Turkmenistan) are reluctant to address issues such as decriminalization of drug use, HR, and replacement therapy (for example, with non-injectable drugs such as methadone). School education on preventing IDU, STIs, and HIV/AIDS is still very limited, although United Nations International Children's Fund (UNICEF) is investing significant resources to scale up this program throughout Central Asia (UNICEF 2002). Many NGOs are active in programs to prevent HIV/AIDS throughout the region, funded by international organizations such as the Soros Foundation/OSI. However, the lack of inter-ministerial cooperation, poor NGO and donor coordination, and poor NGO-donor-Government coordination may pose significant obstacles to effective HIV/AIDS control strategies. In particular, controversial strategies, even though based on solid scientific evidence, are affected by bilateral donor political influences. Public health services and NGOs occasionally cooperate, but partnerships, which may include transfer of funds from the public sector to the NGO sector, should be better developed to ensure coverage of high-risk groups. Integrating NGOs through periodic roundtables and Government funding have been suggested as remedies.
With the exception of Turkmenistan, all Central Asian Governments are developing a regional partnership to decrease IDU and to confront the IDU-based epidemic of HIV/AIDS (see statement from Regional Conference on Drug Abuse in Central Asia, in June, in Taskhent 4 ).
Funding of HIV/AIDS and STI Programs
Most FSU governments are not able to report on expenditures to address HIV/AIDS and STIs. This is partly due to the fact that line item budgets cover inputs such as human resources and pharmaceuticals but not whole programs, and partly due to the secrecy that still dominates some FSU countries. Nevertheless, it is clear that funding available from the public budgets to prevent and treat HIV/AIDS is very limited in all countries.
Because of the renewed focus on poverty through the Millennium Development Goals (MDGs) and because of the war in Afghanistan, Central Asia has become a focus of international political attention. Several organizations have been providing financial and/or technical assistance for research and intervention on HIV/AIDS, STIs, and TB; these include UN agencies, bilateral agencies such as USAID, the German Development Bank (KfW) and Department for International Development (DFID), and international NGOs such as the Soros Foundation/OSI, and the AIDS Foundation East West. These partnerships need continued development and funding. However, available indigenous capacity only allows for limited research and pilot activities but not scaling up of these activities to cover high-risk groups and marginalized populations, let alone the bridge populations to other groups.
More than $15 million is immediately necessary to cover the estimated number of IDUs in Central Asia using a package of services including disposable syringes, condoms, and education about the transmission of the infection. However, given the large numbers and inaccessibility of IDUs, this figure might be a gross underestimation of needs, especially with respect to the supply of needles and the resources necessary to distribute them. Pilot programs reach only a few thousand IDUs, and thus scaling up will require enormous additional resources. According to recent estimates, about US$ 1 billion would be necessary for HIV/AIDS prevention and treatment in Central There is the risk, however, that if significant funding becomes available in the near future, Governments might consider that prevention activities are covered by international organizations, and allocate Government funds mainly to diagnosis and treatment activities. As the funding available from other sources is not enough to cover all necessary prevention activities, further spread of the epidemic will not be prevented. Furthermore, there is the risk that inappropriate treatment with anti-retroviral drugs will create resistance, as it has been observed throughout the region with inappropriate use of TB drugs. This would complicate significantly the public health approach to HIV/AIDS in the sub region. It might be appropriate, in fact, to limit anti-retroviral treatment schemes to pilots to assure that such regimens can be implemented, including laboratory monitoring, procurement, patient compliance, and health care quality assurance.
Extent of the Tuberculosis Epidemic
The TB situation in Central Asian countries generally fits the pattern of the TB epidemic in Eastern Europe in the 1990s. Kazakhstan bears the largest burden of TB in the region, with almost 50,000 cases of active TB registered in 2001. About 25,000 new cases of TB and 5,000 deaths were reported each year in the late 1990s. The specific number of cases in each country is debatable because case notification is incomplete. For example, in Tajikistan only 10 percent of the estimated smear-positive sputum cases were reported in 2000. Prison data are only variably included in the national TB statistics in these countries as well. Nonetheless, Central Asia has reported the highest TB death rates in the FSU. In the latter 1990s, reported TB incidence rates in Kazakhstan and Kyrgyz Republic even surpassed those in the Russian Federation. Although there is no systematic surveillance of multi-drug resistant TB (MDRTB), rates of MDRTB in some areas of Central Asia and in prisons are believed to be amongst the highest in the world. Serious concerns remain about TB in the sub region: (i) there is an unwillingness or lack of ability of Governments to allocate the necessary funding for DOTS implementation at the national level, including in prisons; (ii) there is inefficiency in utilization of available public resources and donor funding; and (iii) the treatment of MDRTB in Kazakhstan and Kyrgyz Republic before satisfactory DOTS implementation is ill advised.
TB surveillance varies across the Central Asian countries. In Kazakhstan, the TB Electronic Surveillance Case-Based Management System (ESCM), developed with assistance of the US CDC, became fully operational throughout the country in 2000, but it is unclear whether it is still in use; in Kyrgyz Republic, surveillance is case-based reporting according to World Health Organization (WHO) standards; in other countries surveillance is mostly carried out according to the old Soviet reporting system, or in pilot Directly Observed Treatment Short-Course (DOTS) programs by WHO and international NGOs such as Medecins Sans Frontieres (MSF) and Project HOPE. Consequently, case notification rates vary considerably across the sub region (Table 4) .
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The TB problem is notable with respect to the HIV/AIDS epidemic. TB in many regions of the world is the chief opportunistic infection causing mortality among HIV/AIDS patients. Thus, control of TB is interrelated with HIV prevention, particularly in closed environments such as prisons, where confined space leads to increased TB risk, and deprivation leads to IV drug use as well as homosexual risk behavior. TB in prisons is known to be an epidemiological pump that fuels generalized epidemics in other parts of the ECA region. Little has been done as yet to address HIV within prisons populations, but as both TB and HIV tend to co-exist in such closed environments, it is likely that dual epidemics will be observed among prison populations. Given the relatively large burdens of TB described above, it is also likely that there will be overlap of these epidemics in the general population unless effective prevention methods are implemented. In particular, special attention is needed to assure that TB-infected and partially treated prisoners are followed through public health and social service mechanisms to assure completion of TB therapy. In addition, it is also likely that VCT for all TB patients will be en effective prevention approach for HIV in this population.
DOTS Implementation
All countries have adopted the WHO-recommended DOTS approach. However, there are several concerns regarding TB treatment in the region: (i) there is limited coverage and implementation of DOTS, as reflected in the low treatment success rates and high rates of MDRTB; (ii) there is also partial or total lack of coverage within prisons, which are considered the epidemiological pump for the TB epidemic in the region; and (iii) in some countries, TB specialists tend to start treatment with second-line drugs before satisfactory DOTS implementation.
DOTS coverage varies significantly across the region, from Kyrgyz Republic and Kazakhstan with almost 100 percent of the population covered with DOTS, to Turkmenistan with 34 percent population coverage, to Uzbekistan with quite slow DOTS implementation, and lastly to Tajikistan, where DOTS program was halted because of civil war (Table 5) . TB treatment success is only moderate in those Central Asian countries that have implemented DOTS. Kyrgyz Republic, where DOTS was first introduced in the region, ranks the best, but the treatment success rate was still below the WHO target of 85 percent cure rates in patients newly registered for treatment in 1999 (Table 6) and HIV/AIDS approaches in Central Asia are not yet integrated, and there is lack of clarity about responsibilities for treatment of AIDS patients with TB. Kazakhstan and Kyrgyz Republic have asked the GFATM for funds to scale up DOTS Plus, which is an extension of the time used for DOTS treatment and use of second-line drugs for treatment. However, this may be premature, given that DOTS has not been fully implemented and that there is no systematic surveillance of MDRTB. In addition, the treatment protocols used in many of the FSU countries are not evidence-based. There is, therefore, a risk of establishing resistance to second-line drugs, as with first-line drugs, due to inappropriate usage, leaving the region and the world at large with an additional public health dilemma. 
Funding of TB Programs
NGO and Partner Activity
Several international NGOs and organizations have been assisting the Governments of Central Asia to adopt and implement the DOTS Strategy, and they have also had a key role in surveillance, diagnosis, and treatment of TB in the region. WHO provides technical assistance for DOTS implementation throughout Central Asia. USAID/CAR, through Project HOPE and CDC, has been assisting DOTS pilot projects in all Central Asian countries, including in prisons. This assistance includes upgrading surveillance systems and laboratories and training TB specialists and other health professionals on proper diagnosis and treatment of TB. MSF has supported DOTS pilot projects in the Aral Sea region in Turkmenistan and Uzbekistan, where TB rates are especially high. KfW, the German Development Bank, has been providing grants for procurement of firstline drugs, laboratory equipment, and supplies in Kyrgyz Republic and Uzbekistan. The Global HIV/AIDS AND TUBERCULOSIS IN CENTRAL ASIA 7 The World Bank has also provided financial and technical support for DOTS implementation in Kazakhstan, Kyrgyz Republic, and Uzbekistan through health projects that have been implemented in those countries. In Kazakhstan, the Bank-financed project has closed, but the Government and the Bank are co-financing sector work, which involves a review of the TB Program. In Kyrgyz Republic, the Bank-financed project is under implementation, and additional sector work may also be eventually carried out in this area. In Uzbekistan, the Health I project is under implementation, and the Government is preparing with Bank assistance the Health II Project, which may continue to support scaling up the DOTS implementation throughout the country.
Health System Issues in Central Asia
Initial estimates of actual and projected cases of HIV and AIDS are based on incomplete and unreliable information. Three sources of data are used in the Country Profiles: official statistics (passively collected in most cases); Government and NGO estimates of IDUs and other groups at risk; and occasional sentinel surveillance data (special studies). Official data provided by the Ministries of Health cover required reported HIV/AIDS cases as well as IDUs under treatment and estimated CSWs. However, UNAIDS has estimated the number of IDUs and HIV-positive cases to exceed registered cases by 5-to 10-fold. Although Ministries of Health, partner organizations, and NGOs have carried out several seroprevalence and behavioral studies, evidence for actual seroprevalence as well as knowledge, attitudes, and practices (KAP) among groups most at risk and youth in general is still scant. Using US Agency for International Development (USAID) resources, CDC is initiating sentinel seroprevalence and behavioral surveys in Kazakhstan and Uzbekistan, and it is providing technical assistance and equipment necessary to establish sentinel surveillance throughout the region for the highly vulnerable groups (USAID/CAR 2002).
One of the major issues involving both HIV/AIDS and TB is the way in which specific illnesses are compartmentalized within FSU health systems. For example, HIV is tested and AIDS treated generally only in a referral infectious disease setting; TB may be separately managed in a pulmonary or TB hospital; prison systems have a separate hospital system; and IDU is treated in narcology centers, if at all. There is a lack of an overriding public health approach that integrates information systems, monitoring and evaluation of risks, communications, and social services. In many cases, the World Bank may support this lack of integration through health systems development projects that manifest as independent segments. These problems require an integrated approach, working across sectors, with a sense of common purpose. There is a lack of integration and cooperation among primary health care and specialized hospital services, specialized AIDS Centers, TB Institutes and Dispensaries, and the Dermatology and Venereal Disease Institutes for prevention and treatment of STIs, HIV/AIDS, and opportunistic infections, of which TB is the main one. STI syndromic case management needs to be better developed, both to reduce morbidity and to reduce the risk of HIV transmission through ulcerative STIs. Hospitals, TB services, and oncological dispensaries are expected to provide treatment of AIDS opportunistic diseases as well as palliative care, but this depends on correct diagnosis, appropriate referral, and availability of anti-retroviral drugs and monitoring systems to support their use. Anti-retroviral treatment of HIV/AIDS is not yet available throughout the region due to its high cost. For example, in Kazakhstan, only children under 15 and infected pregnant women have access to anti-retroviral treatment. If the epidemic grows as expected, both the demand for such treatment and the infrastructure necessary to support it will drain health resources from other important priorities. (These include the growing epidemic of cardiovascular and neoplastic diseases throughout the sub region, diseases which also require significant tertiary medical resources.)
Health systems in general are under-financed in the sub region. This under-financing will create a future tragedy of large proportions if prevention activities, as outlined below, are not addressed and scaled up. Even if sufficient funding is available, there may not be enough local capacity (public services and NGOs) to scale up activities for the majority of groups at risk. Throughout the region, recently established AIDS treatment and support services are still considered relatively unimportant, which raises issues of lack of power among the vulnerable groups to assert needs and lack of institutional capacity to integrate services. In addition, institutional barriers, such as the tradition of dermatology and venerealogical services should be addressed in the implementation of effective and integrated HIV/AIDS and STIs strategies. Building local institutional capacity, which is necessary in order to integrate HIV/AIDS into existing structures, was identified as one of the most urgent tasks in Tajikistan, Turkmenistan, and Uzbekistan.
Health systems in Central Asia have suffered deterioration with respect to disease surveillance as well as coverage for treatment of infectious diseases. This deterioration is an important determinant of success of prevention activities because treatment of STIs, particularly ulcerative diseases such as syphilis and chancroid, is essential to preventing spread of HIV. Moreover, functional STI treatment systems, coupled with voluntary counseling and testing of all patients for HIV, is an important component of prevention (Bos etal. 2002) . The risks for HIV spread are identical to those for other STIs.
Additional financing issues revolve around underserved and thus highly vulnerable populations. Migrants, mobile populations, CSWs, and other hard-to-reach groups often do not have rights to health care, either because of registration status, social isolation, or because of inhospitable health care facilities. In addition, corruption within health care systems, may force vulnerable populations to pay out-of-pocket expenses in the form of bribes or 'envelope' money before services are rendered. Youth-friendly clinics are not as yet a commonly accepted method of reaching at-risk youth. Thus, highly vulnerable populations may not be appropriately treated, either for STIs, TB or HIV-related complications. TB and HIV demand careful follow-up, and if patients with these infections cannot or will not access services, drug resistance will develop (to both TB drugs and antiretrovirals), thus complicating the control of these infectious diseases at the global level. To address this issue, financing options that support the control of infectious diseases as a public good are needed. It is not enough to simply implement a health insurance system, but rather a public goods system of financing critical medications for global public health problems is needed. The World Bank needs to confront this need in its work on health financing systems. Privatization in the context of communicable diseases control has limited utility, and insufficient financing of pharmaceutical systems in this context provides a significant barrier to control HIV/AIDS and TB.
